Provenge News

erisian
Member Posts: 107
http://www.zerocancer.org/site/News2?page=NewsArticle&id=11424
Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented
"These data confirm the survival advantage of Provenge over placebo for men with hormone-refractory prostate cancer. It is anticipated that these findings will result in FDA approval of Provenge."
Let's hope so.
Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented
"These data confirm the survival advantage of Provenge over placebo for men with hormone-refractory prostate cancer. It is anticipated that these findings will result in FDA approval of Provenge."
Let's hope so.
0
Comments
-
More info
"...PROVENGE increased three-year survival by 40 percent compared to placebo (32.1 percent vs 23.0 percent), the median survival difference of PROVENGE compared to placebo was maintained at 4.1 months, with a 24.1 percent reduction in the risk of death..."
Here are a couple of links on the subject:
Dendreon press release:
http://tinyurl.com/Provenge-PR
PDF of presentation on the IMPACT study given at ASCO-GU conference:
http://tinyurl.com/Provenge-pdf0
Discussion Boards
- 119K All Discussion Boards
- 5 CSN Information
- 5 Welcome to CSN
- 119.1K Cancer specific
- 2.7K Anal Cancer
- 423 Bladder Cancer
- 297 Bone Cancers
- 1.6K Brain Cancer
- 28.1K Breast Cancer
- 375 Childhood Cancers
- 27.6K Colorectal Cancer
- 4.5K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.6K Head and Neck Cancer
- 6.2K Kidney Cancer
- 638 Leukemia
- 764 Liver Cancer
- 4K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 213 Multiple Myeloma
- 7.1K Ovarian Cancer
- 34 Pancreatic Cancer
- 477 Peritoneal Cancer
- 5K Prostate Cancer
- 1.1K Rare and Other Cancers
- 519 Sarcoma
- 689 Skin Cancer
- 633 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.6K Uterine Cancer
- 6.2K Other Discussion Boards